Navigation Links
Breakthrough System for Understanding Ocean Plant Life Announced

Sixty million people in 36 countries of sub-Saharan Africa are threatened daily by a deadly parasitic disease known as African sleeping sickness. The disease is caused by organisms called trypanosomes, which are spread by the tsetse fly. African sleeping sickness affects approximately 500,000 people in sub-Saharan Africa, a quarter of whom will die this year. Because the trypanosome has an exceptional genetic strategy for evading the human immune system and resisting treatment, the current treatment for this disease is melarsopal, an antiquated drug with terrible side effects, including death.

In the February issue (Volume 17, Issue 3) of the journal Molecular Cell, scientists in the Marine Biological Laboratory's (MBL's) Josephine Bay Paul Center for Comparative Molecular Biology and Evolution report their discovery of a protein called JBP2, which will help them test their hypothesis that a uniquely modified DNA base called base J is a key component of the trypanosome's mechanism for evading the immune system. If the hypothesis is correct, it will bring scientists closer to developing a more effective drug for treating African sleeping sickness.

The trypanosome evades the human immune system because it is coated with a surface antigen called variant surface glycoprotein (VSG). The human body makes antibodies for VSG, but trypanosomes randomly switch to another antigen when the organisms divide and reproduce. Trypanosomes whose VSG has switched evade the antibodies the human immune system made to fight the original antigen, thus assuring the long-term survival of these parasites within their hosts. The trypanosome has approximately 1,000 different VSG genes, but only expresses one at a time while the others are somehow silenced. This genetic trick, called antigenic variation, has severely limited sleeping sickness treatment options and essentially ruled out the possibility of a vaccine.

MBL trypanosome experts in Robert Sabatini's lab hypothes
'"/>

Source:


Page: 1 2

Related biology news :

1. Breakthrough Microarray-based Technology for the Study of Cancer
2. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
3. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
4. Breakthrough isolating embryo-quality stem cells from blood
5. Breakthrough: Scientists create worlds tiniest organic particles
6. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
7. Sciences Breakthrough of the Year: Watching evolution in action
8. Breakthrough for stem cell research
9. Breakthrough in understanding type-2 diabetes as key genes identified
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. Genes In The Interferon System Important In Systemic Lupus Erythematosus

Post Your Comments:
(Date:11/23/2009)... available in German . , A bit of imaginati...be a bad thing. It could help to add data from are...ver, it must do so constructively. In order to inf...h more than just imagination, physicists at the Ma...d a theory of spatial perception called informatio...
(Date:11/22/2009)...ring South Korean scientists have succeeded in pro...ough bioengineering, rather than through the use o... research, which may now allow for the production ...d in two papers in the journal Biotechnology and ...sary. , Polymers are molecules found in everyda...
(Date:11/22/2009)...e Brain Research Centre, a partnership of the Univ... Vancouver Coastal Health Research Institute, have...which brain cells die following a stroke, as well ...ults of the study were recently published online i...brain cells continue to die even after blood flow ...
Breaking Biology News(10 mins):Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 4Bioengineers succeed in producing plastic without the use of fossil fuels 2New understanding about mechanism for cell death after stroke leads to possible therapy 2KGI Establishes Post Baccalaureate Premedical Program 58514 1KGI Establishes Post Baccalaureate Premedical Program 58514 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 1Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 3InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 1InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 2
...nywhere in the world soon could be made completely...rside geneticists, done in collaboration with scie...arch Institute in the Philippines. By gradually in...nce," a property that enables rice to survive extr...entially any variety of rice could be made to surv...
...fluenza vaccines may increase elderly patients, im... offering this vulnerable population additional pr...in the May 22 issue of Archives of Internal Medici...containing inactivated influenza virus have been a...ications, according to background information in t...
...f Minnesota researchers have discovered how a prev...r year in the United States overcomes the effects ...e of its chromosomes. , Candida albicans, a type...lly harmless. In otherwise healthy people, it can ...or thrush) that are easily treated. But in people ...
Other Biology News:Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3High-dose flu vaccines appear to safely boost immunity in elderly 2U of M researchers discover genetic key to treating deadly fungal infections 2
(Date:11/20/2009)...-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasd...ircuit Court of Appeals reversed a U.S. District C... pursue all of its claims against The Lash Group, ...ial. CTI filed a complaint against The Lash Group...t for CTI,s product TRISENOX, in 2007 seeking $22....
(Date:11/19/2009)...stCall/ -- Omeros Corporation (Nasdaq: OMER ) tod...hird quarter ended September 30, 2009. For the thr...d a net loss of $3.9 million, or $1.34 per share, ...4 per share, for the same period in 2008. For the ...reported a net loss of $15.5 million, or $5.29 per...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)...d by latest award for revolutionary hearing aid. ...ber 16, 2009 -- Popular Science Magazine has named...m InSound Medical a winner of its coveted Best of ...p;   Chosen from thousands of entra...ng canal for up to four months while providing nat...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...d, Ph.D., Joins as Chief Executive Officer, MENLO...y, Inc. (FAB), a privately held biotechnology comp...ies B financing. Prior investor SV Life,Sciences (...lta Partners.,The proceeds from the financing will...synthesis technology to produce biologic drugs and...
...urg Regional Education Consortium Promoting Advanc..., Dec. 7 High school and,college students from th...anced technology careers and curriculum through a ...s and the commonwealth., At BioTech Day 2007, hos...chnology, Community and Economic Development Deput...
...D, Calif., Dec. 7 Ardea Biosciences,Inc. (Nasdaq:...ief Executive,Officer, Barry D. Quart, PharmD, wil...eatment" panel discussion at the RBC Capital Marke...er 12, 2007 at 1:30 p.m. (ET) at,the Westin Times ...t of the,presentation and panel discussion will be...
Other Biology Technology:Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 2Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 3Capital Area Biotechnology Partnership Receives $160,000 State Investment 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3
ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Assay Diluent from BD Biosciences Pharmingen
Biology Products: